Celularity, Inc. (NASDAQ:CELU) Sees Significant Growth in Short Interest

Celularity, Inc. (NASDAQ:CELU) saw a significant growth in short interest in December. As of December 31st, there was short interest totaling 483,285 shares, a growth of 26.6% from the December 15th total of 381,786 shares. Based on an average trading volume of 108,359 shares, the days-to-cover ratio is presently 4.5 days. Approximately 2.1% of the company’s shares are short sold. Approximately 2.1% of the company’s shares are short sold. Based on an average trading volume of 108,359 shares, the days-to-cover ratio is presently 4.5 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celularity in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Celularity presently has a consensus rating of “Hold” and a consensus price target of $6.00.

Celularity Stock Up 1.6%

Shares of NASDAQ CELU opened at $1.31 on Monday. The business’s 50 day moving average price is $1.55 and its two-hundred day moving average price is $2.21. The company has a market cap of $37.31 million, a PE ratio of -0.39 and a beta of 0.80. Celularity has a twelve month low of $1.00 and a twelve month high of $4.35.

Celularity (NASDAQ:CELU) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.62. The business had revenue of $5.28 million during the quarter.

Institutional Investors Weigh In On Celularity

Several hedge funds have recently bought and sold shares of CELU. Perennial Investment Advisors LLC bought a new position in shares of Celularity during the third quarter worth approximately $28,000. Acadian Asset Management LLC acquired a new stake in Celularity in the first quarter valued at about $34,000. XTX Topco Ltd grew its position in Celularity by 106.4% in the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after acquiring an additional 11,057 shares during the last quarter. Bank of America Corp DE lifted its stake in Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after purchasing an additional 35,023 shares during the last quarter. Finally, HB Wealth Management LLC bought a new stake in Celularity during the 3rd quarter worth $84,000. 19.02% of the stock is currently owned by institutional investors and hedge funds.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.